Viral Variants and Vaccinations: If We Can Change the COVID-19 Vaccine... Should We?

3

4 Sharon Bewick¹

⁵ ¹Department of Biological Sciences, Clemson University, Clemson, South Carolina, U.S.A

6

7 Abstract

As we close in on one year since the COVID-19 pandemic began, hope has been placed on 8 9 bringing the virus under control through mass administration of recently developed vaccines. 10 Unfortunately, newly emerged, fast-spreading strains of COVID-19 threaten to undermine 11 progress by interfering with vaccine efficacy. While a long-term solution to this challenge would 12 be to develop vaccines that simultaneously target multiple different COVID-19 variants, this 13 approach faces both developmental and regulatory hurdles. A simpler option would be to switch 14 the target of the current vaccine to better match the newest viral variant. I use a stochastic 15 simulation to determine when it is better to target a newly emerged viral variant and when it is 16 better to target the dominant but potentially less transmissible strain. My simulation results 17 suggest that it is almost always better to target the faster spreading strain, even when the initial prevalence of this variant is much lower. In scenarios where targeting the slower spreading 18 19 variant is best, all vaccination strategies perform relatively well, meaning that the choice of 20 vaccination strategy has a small effect on public health outcomes. In scenarios where targeting 21 the faster spreading variant is best, use of vaccines against the faster spreading viral variant can 22 save many lives. My results provide 'rule of thumb' guidance for those making critical decisions 23 about vaccine formulation over the coming months.

24

25 Introduction

26 On March 11, 2020, the World Health Organization (WHO) declared the COVID-19 27 outbreak a global pandemic¹. Since then, much effort has focused on developing safe and 28 effective vaccines that can bring the world back to normality². Remarkably, exactly 9 months 29 after the WHO declared a global pandemic, the U.S. Food and Drug Administration (FDA) 30 announced an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 31 vaccine³ – the first vaccine against COVID-19 to receive approval in the United States. 32 Additional authorizations have followed rapidly. For instance, an EUA was issued for the 33 Moderna COVID-19 vaccine a mere one week after the EUA for the Pfizer-BioNTech vaccine⁴. 34 Notably, this timeline for vaccine development and approval is over four times faster than any previous vaccine efforts⁵. Further, initial clinical trials suggest that these early vaccines against 35 COVID-19 are highly effective, with both Pfizer-BioNtech and Moderna reporting efficacies 36 37 exceeding 90%^{6,7}, which is comparable to some of the best vaccines currently in use. 38 In large part, the remarkable speed with which the world has developed safe, efficacious 39 COVID-19 vaccines is a result of years of advances in molecular biology. Indeed, both the Pfizer-BioNTech vaccine and the Moderna vaccine rely on a novel messenger RNA (mRNA) 40 41 approach^{8,9} for stimulating the immune system. Though there are some drawbacks of mRNA 42 vaccines – most notably the requirement for cold-chain storage – this technology greatly 43 facilitates rapid and targeted vaccine development based solely on the genetic sequence of the 44 virus¹⁰. This, in turn, allows vaccine candidates to be made without ever needing to culture the 45 virus itself. Another related advantage of mRNA vaccines is their flexibility. In particular, 46 because their only requirement is the genetic code for a particular antigenic component of the 47 target virus, it is not difficult to alter these vaccines in response to strain variation.

48	In early December 2020, the United Kingdom reported a novel and potentially
49	concerning COVID-19 variant, B.1.1.7 ^{11,12} . What is particularly troublesome about this variant is
50	that it has a large number of mutations – 23 in total, 17 of which are non-silent ¹² . Further, 8 of
51	these mutations occur in the spike protein, which is the portion of the virus responsible for
52	enabling viral entry into human cells ¹² . These novel mutations include the N501Y mutation that
53	allows the virus to bind more tightly to the human angiotensin converting enzyme 2 (ACE2)
54	receptor ¹³ , as well as the D614G deletion that appears to make the virus more transmissible
55	between individuals ¹⁴ . Substantial genetic changes, along with accelerating rates of spread, and a
56	rapid rise to dominance of the B.1.1.7 variant in Southern England ¹⁵ , suggest that the B.1.1.7 has
57	a fitness advantage. In fact, recent modeling studies indicate that the B.1.1.7 variant could be 50-
58	70% more transmissible than previous COVID-19 strains ^{11,16} .
59	Beyond altered transmissibility, another threat of the B.1.1.7 mutant is that existing
60	vaccines may be less effective against it. This is because most vaccines in development
61	specifically target the viral spike protein ² . Currently Pfizer-BioNTech and Moderna are
62	conducting in vitro assays that will provide first estimates of the efficacy of existing vaccines
63	against the novel B.1.1.7 COVID-19 variant. Full assessment of vaccine efficacy will follow in a
64	matter of weeks to months, as existing vaccines are rolled-out in locations like Southern England
65	where the B.1.1.7 variant is dominant. However, even if current vaccines are efficacious against
66	B.1.1.7, the emergence of this viral variant is a warning call. In particular, we can expect
67	COVID-19 to continue to mutate and to generate novel variants that differ from the initial
68	vaccine targets. The obvious long-term solution is to develop vaccines that contain DNA from all
69	of the dominant COVID-19 variants in circulation (multivalent), much like the seasonal
70	influenza vaccine ¹⁷ . However, because mRNA vaccine technology is new, multivalent COVID-

71 19 mRNA vaccines have not been tested. Thus, it is unclear whether presenting multiple 72 antigenic components through mixed mRNAs will actually provide even immune coverage to all components, or whether there will be interference effects¹⁸. Likewise, it is unclear whether there 73 74 are any additional health risks to mixed mRNA vaccines. As a consequence, multivalent 75 COVID-19 vaccines pose both development and regulatory hurdles. A simpler approach to 76 combat COVID-19 strain evolution is to 'switch out' the viral mRNA in the existing single strain 77 (monovalent) vaccine in response to changes in the dominance of the circulating strains. 78 Currently, for example, that could mean switching to the mRNA for the spike protein from the 79 B.1.1.7 viral variant. 80 While it may seem obvious that COVID-19 vaccines should be altered to track the 81 dominant viral strains in circulation, there are costs involved with switching. Further, without 82 sufficient cross-protection, vaccination against one viral variant will cause the other to rise to dominance and vice versa, essentially leading to a game of whack-a-mole. While this scenario 83 84 cannot be avoided entirely, there may still be better and worse decisions in terms of the viral 85 variant that is selected for vaccine efforts. This is because not all viral variants are biologically equivalent. Some viral variants, like B.1.1.7 are more transmissible. Others may be more 86 87 prevalent, or may have already swept a larger fraction of the population, at least at the time of the initial vaccine roll-out. This, then, begs the question: When multiple COVID-19 viral variants 88 89 are circulating, and when vaccine cross-protection is not complete, which variant should be 90 targeted for vaccine scale-up during the initial vaccination phase? 91 In this paper, I use a simple stochastic simulation to examine the outcomes of various

93 examine how the best choice of vaccine target depends on the degree of cross-protection offered

vaccine strategies against two different co-circulating COVID-19 viral variants. In particular, I

92

by vaccination and/or natural immunity to the alternate strain. I also consider how outcomes
depend on the relative transmissibilities of the different viral variants, their relative prevalence at
the beginning of the vaccination period, and existing natural immunity. Finally, I consider how
differences in the timing of vaccine roll-out can change predictions, and what this might mean as
we rapidly scale-up a series of different mRNA vaccines against the COVID-19 pandemic.

99

100 Method

I use the Gillespie algorithm $(GA)^{19}$ – a discrete-time, event-based simulation approach – to study 101 102 transmission of two different COVID-19 viral variants in a human population undergoing rapid 103 roll-out of a COVID-19 vaccine that is targeted at only one of the two variants (monovalent). For 104 each individual in the population, I assume that they can be in one of four potential infection 105 classes, one of four potential natural immunity classes and one of four potential vaccination 106 classes. Specifically, individuals can be: virus-free (i = 0), infected with the first viral variant (i = 0)107 1), infected with the second viral variant (i = 2) or infected with both viral variants (i = 3). 108 Likewise, individuals can be: fully naturally susceptible (i = 0), naturally immune to the first 109 viral variant (i = 1), naturally immune to the second viral variant (i = 2) or naturally immune to 110 both viral variants (i = 3). Finally, individuals can be: unvaccinated (k = 0), vaccinated against 111 the first viral variant (k = 1), vaccinated against the second viral variant (k = 2) or vaccinated 112 against both viral variants (k = 3). Ultimately, this leads to $4 \times 4 \times 4 = 64$ possible states for each 113 individual. I then define a matrix, N, where each element, $N_{i,i,k}$, specifies the number of individuals in the i^{th} infection class, the j^{th} natural immunity class and the k^{th} vaccination class. 114 Depending on model assumptions, not all states may be possible, in which case $N_{i,j,k} = 0$ (e.g., if 115 there are no double vaccinations, then $N_{i,i,3} = 0$). 116

117 Viral Transmission

I assume frequency-dependent viral transmission. Thus, the probability of a new viral infection involving viral variant *i* is proportional to both the number of individuals infected with that variant and the number of individuals susceptible to that variant, and is inversely proportional to total population size. I assume that natural immunity and/or vaccine-induced immunity impact the probability of transmission of each viral variant, but are not necessarily fully protective, even against the 'on-target' viral variant. Specifically

124
$$P_T(N_{i,j,k,t+\Delta t} = n+1, N_{\gamma,j,k,t+\Delta t} = m-1 | N_{i,j,k,t} = n, N_{\gamma,j,k,t} = m)$$

125
$$= \begin{cases} \frac{\beta_{i} \left(1 - \max(\varepsilon_{ji}, v_{ki})\right) N_{\gamma, j, k} \sum_{j, \hat{k}} (N_{i, \hat{j}, \hat{k}} + N_{3, \hat{j}, \hat{k}}) \Delta t}{\sum_{\hat{i}, \hat{j}, \hat{k}} N_{\hat{i}, \hat{j}, \hat{k}}} & i = 1, 2, \gamma = 0\\ \frac{\beta_{\gamma'} \left(1 - \max(\varepsilon_{j\gamma'}, v_{k\gamma'})\right) N_{\gamma, j, k} \sum_{\hat{j}, \hat{k}} (N_{\gamma', \hat{j}, \hat{k}} + N_{3, \hat{j}, \hat{k}}) \Delta t}{\sum_{\hat{i}, \hat{j}, \hat{k}} N_{\hat{i}, \hat{j}, \hat{k}}} & i = 3, \gamma = 1, 2\\ 0 & \text{otherwise} \end{cases}$$

(1)

126

127 where
$$P_T(N_{i,j,k,t+\Delta t} = n + 1, N_{\gamma,j,k,t+\Delta t} = m - 1 | N_{i,j,k,t} = n, N_{\gamma,j,k,t} = m)$$
 is the probability of
128 an individual transferring from the γ infection class to the *i* infection class and $\gamma' = \begin{cases} 1 & \gamma = 2 \\ 2 & \gamma = 1 \end{cases}$.
129 In equation (1), β_i is a parameter that describes the transmissibility of viral variant *i*, ε_{ji} is a
130 parameter that describes the reduction in transmission of viral variant *i* to an individual of
131 immunity state *j* and v_{ki} is a parameter that describes the reduction in transmission of viral
132 variant *i* to an individual of vaccination state *k*. For all models that I consider, I assume that $\varepsilon_{ji} =$
133 v_{ki} when $j = k$ (natural immunity and vaccine induced immunity confer similar levels of
134 protection). Further, I assume that $\varepsilon_{11} = \varepsilon_{22} = v_{11} = v_{22}$ and that $\varepsilon_{12} = \varepsilon_{21} = v_{12} = v_{21}$ (both
135 viral variants perform similarly in terms of the degree of conferred same-strain protection and the
136 degree of conferred cross-strain protection). Notice that equation (1) makes several simplifying

137	assumptions. First, a current infection with one viral variant does not impact the likelihood of a
138	secondary infection with the alternate viral variant. Second, co-infected individuals spread each
139	viral variant at the same rate as if they were singly infected. Third, immunity and vaccination
140	status do not impact the extent to which an infected individual spreads disease. Fourth, co-
141	infections are picked up serially, rather than as a result of direct transfer from a co-infected
142	individual. All of these assumptions could be relaxed, though with the requirement for
143	additional parameters.
144	
145	Recovery
146	I assume a constant probability of recovery of infected individuals. Further, I assume that, upon
147	recovery, an individual acquires natural immunity to the viral variant that they were infected
148	with (or remains naturally immune, if they already had immunity to that particular strain). Thus,
149	$P_R(N_{0,\gamma,k,t+\Delta t} = n+1, N_{i,j,k,t+\Delta t} = m-1 N_{0,\gamma,k,t} = n, N_{i,j,k,t} = m) =$
150	$\begin{cases} r_{i,j,k}N_{i,j,k}\Delta t & i > 0, j = 0, i, \gamma = i \text{ OR } i > 0, j = 1, 2, i \neq j, \gamma = 3 \\ 0 & \text{otherwise} \end{cases}$
151	(2)
152	where $P_R(N_{0,i,k,t+\Delta t} = n + 1, N_{i,j,k,t+\Delta t} = m - 1 N_{0,i,k,t} = n, N_{i,j,k,t} = m)$ is the probability of
153	an individual transitioning from the <i>i</i> infection class to the virus-free infection class ($i = 0$) and
154	the γ immunity class. In equation (2), the rate of recovery can depend on the viral variant, on
155	whether an individual is infected with a single viral variant or is co-infected, and on the
156	immunity and vaccination status of the infected individual. However, in all models that I
157	consider, I assume $r_{i,j,k} = r$; thus all individuals have similar probabilities of recovery,
158	regardless of disease state or immunity status.
159	

160 *Death*

I assume a constant probability of death of infected individuals and do not consider additionaldeath or birth in the population. Specifically

163
$$P_D(N_{i,j,k,t+\Delta t} = n - 1 | N_{i,j,k,t} = n) = \begin{cases} \mu_{i,j,k} N_{i,j,k} & i > 0\\ 0 & \text{otherwise} \end{cases}$$
(3)

where $P_D(N_{i,j,k,t+\Delta t} = n - 1 | N_{i,j,k,t} = n)$ is the probability of an individual from the *i* infection class being removed from the population. In equation (3), the probability of dying depends on the particular viral infection, as well as the immunity status of the host. However, as with recovery, for all models that I consider, I assume that $\mu_{i,j,k} = \mu_i$. This means that death rate is

only a function of the viral variant(s) causing the infection but does not depend on immune statusof the host.

170

171 Vaccination

I assume a constant probability of vaccination, and that vaccination does not take into account the natural immunity status or infection status of the individual. I make this assumption given the large number of asymptomatic infections that make it difficult to know whether a person has been previously infected or, indeed, even whether a person is currently infected. I do, however, assume that people who have already been vaccinated are not re-vaccinated. Finally, I assume that vaccination proceeds at a fixed rate until all individuals willing to receive a vaccine have done so. Once all willing individuals have been vaccinated, vaccination stops. Thus

179
$$P_V(N_{i,j,\kappa,t+\Delta t} = n+1, N_{i,j,k,t+\Delta t} = m-1 | N_{i,j,\kappa,t} = n, N_{i,j,k,t} = m) =$$

180
$$\begin{cases} \omega_{\kappa} \quad k = 0, \kappa = 1, 2, \sum_{\hat{i}, \hat{j}, \hat{k} = 1, 2} N_{\hat{i}, \hat{j}, \hat{k}} / \sum_{\hat{i}, \hat{j}, \hat{k}} N_{\hat{i}, \hat{j}, \hat{k}} < \theta \\ 0 \qquad \text{otherwise} \end{cases}$$
(4)

181 where
$$P_V(N_{i,j,\kappa,t+\Delta t} = n+1, N_{i,j,\kappa,t+\Delta t} = m-1 | N_{i,j,\kappa,t} = n, N_{i,j,\kappa,t} = m)$$
 is the probability of

182 an individual with vaccination status k receiving the vaccine and transitioning to vaccination

183 status κ , ω_{κ} is the rate at which the vaccine is administered and θ is the fraction of the

- 184 population willing to receive a vaccine.
- 185

186 *Parameters and Initial Conditions*

187 Except where noted otherwise, I assume the parameter values as outlined in Table 1. Briefly, I 188 assume that both vaccines and natural immunity are 95% effective at preventing infection when 189 targeted at the same viral variant. This is commensurate with early reports from both Pfizer-BioNTech and Moderna^{6,7}, as well as low reports of re-infection across the world. Likewise, I 190 191 assume that a person who has been infected can spread the virus for 10 days²⁰ (notice that it does 192 not matter whether the person has symptoms for any or all of this period). I assume that the death 193 rate due to disease is 0.0006/day which, for a 10 day infection period, leads to a 0.6% death rate, 194 again commensurate with current reports on COVID-19 infection fatality ratios (IFRs)²¹. Finally, 195 I assume that a person infected with the original COVID-19 variant spreads the disease to, on average, 2 additional people²², while a person infected with the new viral variant spreads the 196 197 disease to, on average, 3 additional people (i.e., 50% more infectious). Finally, I assume that 198 100% of the population is willing to/forced to receive the vaccine, and that 5000 people per day, 199 can be vaccinated in a 500,000 person population (i.e., it takes 100 days or approximately 3 200 months to vaccinate the entire focal population).

For initial conditions, I assume that, at the start of the simulation, a pre-defined fraction of the population, ρ_1 , is infected with the first viral variant, and a pre-defined fraction of the population, ρ_2 , is infected with the second viral variant. I ignore co-infections at the beginning of

204	the simulation under the assumption that $\rho_1 \rho_2 \sum_{\hat{i},\hat{j},\hat{k}} N_{\hat{i},\hat{j},\hat{k}} \ll 1$ for reasonably small ρ_1 and/or ρ_2 .
205	Likewise, I assume that, at the start of the simulation, a pre-defined fraction of the population,
206	φ_1 , is immune as a result of previous infection with the first viral variant, and that a pre-defined
207	fraction of the population, φ_2 , is immune as a result of previous infection with the second viral
208	variant. As with infection, I assume that there are no individuals who have acquired natural
209	immunity to both viruses, which is a good approximation when either φ_1 or φ_2 are small (at least
210	one strain has not been circulating for a long time) or when ε_{12} or ε_{21} are large (natural cross-
211	protection is high, making serial infection with different strains less likely). In practice, most
212	simulations that I consider assume that the second COVID-19 strain is a recent introduction, and
213	thus $\varphi_2 \sim 0$.

214 **Table 1**: Parameters and initial conditions used in simulations

Parameter	Symbol	Value
Natural immunity against same variant	$\epsilon_{11}, \epsilon_{22}$	0.956,7
Natural cross-protection against the opposite variant	E ₁₂ , E ₂₁	0.70
Vaccine induced immunity against same variant	v_{11}, v_{22}	0.95
Vaccine induced cross-protection against the opposite variant	v_{12}, v_{21}	0.70
Recovery rate	r	0.1 ²⁰
Death rate	μ_1, μ_2	0.0006 ²¹
Transmission rate of COVID-19 variant 1	β_1	0.222
Transmission rate of COVD-19 variant 2	β_2	0.3
Fraction of population willing to receive vaccine	θ	1
Vaccination rate	$\omega_1 + \omega_2$	5000
Population size	$\sum_{\hat{\imath},\hat{\jmath},\hat{k}} N_{\hat{\imath},\hat{\jmath},\hat{k}}$	500000
Initial fraction infected with variant 1	$ ho_1$	0.001
Initial fraction infected with variant 2	$ ho_2$	0.00001
Initial fraction naturally immune to variant 1	φ_1	0.10
Initial fraction naturally immune to variant 2	φ_2	0


- 215
- 216 Python code for model simulations is provided at:
- 217 https://github.com/bewicklab/COVID-Vaccination-Strategies

218 **Results**

219 In the analysis that follows, I consider three different vaccination strategies. First, I consider a 220 scenario where all doses of the vaccine are targeted against viral variant 1 (blue lines). Second, I 221 consider a scenario where all doses of the vaccine are targeted against viral variant 2 (red lines). 222 Finally, I consider a scenario where two different types of vaccines are in use, with 50% of the 223 doses targeted against viral variant 1, and 50% of the doses targeted against viral variant 2 224 (purple lines; this could be achieved, for example, if Pfizer-BioNTech and Moderna produced 225 different vaccines, each targeting the opposite viral variant). For each scenario, I consider three 226 metrics: (1) total deaths from the start of the simulation until the virus goes extinct, (2) peak 227 number of infections at any given time and (3) number of days until the virus goes extinct. Total 228 deaths provides an estimate of the costs of the different strategies in terms of human life. Total 229 deaths are also proportional to total infections, thus giving a sense of the overall scale of the viral 230 outbreak for each scenario. Peak number of infections is important, because an outbreak that has 231 a higher number of infectious individuals at any single point in time is more likely to overwhelm 232 healthcare facilities. Thus, even if the total sizes of two different outbreaks are the same, death 233 rates are likely to be lower for the outbreak with a lower peak infection rate (which typically 234 implies an outbreak that is spread over a longer period of time – note that my model assumes a 235 constant death rate, thus total deaths does not account for variation in death rate due to 236 overwhelmed medical facilities). Finally, the number of days until the virus goes extinct gives a 237 sense of the time required to reach herd immunity through a combination of natural infection and 238 vaccination. Longer times to viral extinction do not necessarily mean worse outbreaks in terms 239 of total infections and deaths, although they do imply a longer period over which masks and

social distancing may be required, particularly for at-risk people. For all simulations, I assume





243

244 Fig. 1 (A) Total number of deaths, (B) peak infections and (C) time to virus extinction as a function of the degree of natural and vaccine-induced cross-protection ($v_{12} = v_{21} = \varepsilon_{12} = \varepsilon_{21}$) 245 assuming a vaccination strategy targeting viral variant 1 (blue, slower spreading), a vaccination 246 strategy targeting viral variant 2 (red, faster spreading) and a mixed strategy with 50% of the 247 248 population receiving the vaccine against viral variant 1 and 50% receiving the vaccine against 249 viral variant 2. All parameters and initial conditions except those associated with crossprotection $(v_{12}, v_{21}, \varepsilon_{12}, \varepsilon_{21})$ are as defined in Table 1. Results shown are median values over 30 250 251 simulation trials.

252

253 Degree of Cross-Protection

Figure 1 shows the total number of deaths (A), peak infections (B) and time to virus extinction

- 255 (C) as a function of the degree of cross-protection offered by natural immunity and/or
- 256 vaccination to the opposite viral variant. For these simulations, I assume a total population size
- of 500,000 individuals, and an IFR of 0.6%. Consequently, if the entire population is infected

with one of the two virus strains, then approximately 3000 individuals will die. Likewise, if the
entire population is infected with both of virus strains (simultaneously or sequentially), then
approximately 6000 individuals will die. Because herd immunity is typically achieved at
infection rates less than 100%, 3000 and 6000 deaths represent upper bounds for single
infections and double infections respectively. Nevertheless, these bounds help to frame
simulation results.

264 As expected, when cross-protection is close to zero, vaccination against one of the two 265 viral strains cuts the total death rate in half. However, it does nothing to prevent deaths from the 266 off-target viral variant. Because of this, vaccination against the more transmissible virus (in this 267 case, viral variant 2) is almost always optimal, even if the less transmissible virus is initially 268 present at substantially higher rates. This is because, regardless of initial conditions, the off-269 target variant will inevitably sweep the population. The virus that is more transmissible, 270 however, will infect a higher proportion of the population prior to reaching herd immunity. 271 Consequently, vaccinating against this more transmissible strain is the better option when there is 272 little to no cross-protection.

273 Although faster spread of viral variant 2 is the primary factor favoring use of this strain as 274 the vaccine target at low levels of cross-protection, there are two additional advantages to 275 focusing on viral variant 2. Both are related to the fact that viral variant 1 is more prevalent. 276 While somewhat counterintuitive, higher prevalence of a particular strain prior to vaccination 277 can actually make it less effective to target that strain with the vaccine (see Fig. 5). This is 278 because higher viral prevalence goes hand-in-hand with higher levels of natural immunity, which 279 has two consequences. First, if one of the two viral variants will inevitably sweep the population 280 (i.e., low cross-protection), then it is preferable that this be the variant with more existing natural

immunity, since fewer additional deaths will be necessary to reach herd immunity. Second, when
the vaccine is targeted against the more prevalent variant, more vaccine doses are wasted
protecting individuals who are already naturally immune (see Figure 5). By contrast, wasted
vaccine doses less common when the vaccine protects against a strain without much pre-existing
natural immunity. Again, this disfavors use of the more prevalent strain as the vaccine target (in
this case, variant 1).

287 Interestingly, a relatively high level of cross-protection is required before vaccination with the more prevalent but slower spreading variant becomes a competitive strategy. Increasing 288 289 cross-protection from 0% to 50%, for instance, only reduces total deaths by <30% when the 290 vaccine is targeted against the prevalent but slow spreading variant 1. By contrast, cross-291 protection has a much stronger effect earlier on when the vaccine is targeted against the fast 292 spreading variant 2. In this case increasing cross-protection from 0% to 50% causes a >70%293 reduction in deaths. Notably, even at 90% cross-protection, vaccination against the slow 294 spreading variant still underperforms in terms of preventing deaths. 295 Surprisingly, a mixed strategy, where half of the population receives the vaccine against 296 the slow spreading variant, while the other half receives the vaccine against the fast spreading 297 variant, performs almost as well as fully targeting the fast-spreading variant. This is particularly 298 notable, since a mixed strategy may be more realistic to implement, at least in the near-term, for 299 COVID-19. A mixed strategy, for example, would only require one or a few vaccine-makers to 300 alter the formulations of their vaccines. Notice, however, that my simulations assume randomization of the two vaccines throughout the entire vaccine roll-out period – thus results 301

302 could be different if the two different vaccines were rolled out on different timelines or in

303 different spatial locations.

304	Like deaths, peak infections are also much higher under the scenario with vaccination
305	against the prevalent but slow spreading variant 1. Interestingly, however, peak infections are
306	also higher for the mixed vaccination strategy as compared to vaccination against viral variant 2,
307	at least when cross-protection <50%. This contrasts what was seen for total deaths. Nevertheless,
308	the mixed strategy still performs substantially better than vaccination against the slow spreading
309	variant 1 over most of the range of potential cross-protection levels. At high cross- protection,
310	(80-90%), differences in the different vaccination strategies are minimal, and the mixed strategy,
311	or even vaccination against the slow spreading viral variant can actually yield lower peak
312	infection levels.
312 313	infection levels. Times to viral extinction tend to be unimodal, at least for strategies that target a single
313	Times to viral extinction tend to be unimodal, at least for strategies that target a single
313 314	Times to viral extinction tend to be unimodal, at least for strategies that target a single viral variant. This is because, at low cross-protection, the off-target variant rapidly sweeps the
313 314 315	Times to viral extinction tend to be unimodal, at least for strategies that target a single viral variant. This is because, at low cross-protection, the off-target variant rapidly sweeps the population, driving its own demise over a short period of time (at least in the absence of
313 314 315 316	Times to viral extinction tend to be unimodal, at least for strategies that target a single viral variant. This is because, at low cross-protection, the off-target variant rapidly sweeps the population, driving its own demise over a short period of time (at least in the absence of introduction of newly susceptible individuals through birth or waning immunity). Meanwhile the

320 longer persistence of this strain in the population. While viral persistence peaks around 40%

321 cross protection for the mixed strategy and the strategy that targets the fast-spreading variant 2, it

322 peaks at a much higher 70% cross protection for the strategy that targets the slow-spreading

323 variant 1. Alarmingly, when the vaccine targets viral variant 1, the virus can persist nearly 1.5


324 years after vaccination begins, even with a rapid vaccine roll-out of 3 months.

325


326

327 **Relative Transmission Rates**

- 328 Figure 2 shows the total number of deaths (A), peak infections (B) and time to virus extinction
- 329 (C) as a function of the transmission rate of the faster spreading viral variant 2. In these
- 330 simulations, I assume that viral variant 1 spreads at a rate of 0.2 person⁻¹day⁻¹. For a typical







339

340 infectious period of 10 days, this means that each person, on average, spreads the virus to two

- 341 additional people in a fully susceptible population. This estimate is commensurate with current
- 342 measures of R_0 for COVID-19²². By extension, for the range of transmissibilities considered in
- 343 Figure 2, each person infected with viral variant 2 transmits the virus to between 2 and 4

344 additional individuals in a fully susceptible population. This is in keeping with the estimate that the new B.1.1.7 COVID-19 strain is 50-70% more transmissible than its predecessor^{11,16}. Not 345 346 surprisingly, increasing transmissibility of the second viral variant increases overall deaths, as 347 well as peak infections at the height of the outbreak. However, the rate of increase depends on 348 vaccination strategy. When there is not much difference between the transmission rates of the 349 two viral variants, it is actually best to vaccinate against the more prevalent but slower spreading 350 viral variant 1. This is because the second viral variant is 100-fold less common at the beginning of the simulation. Thus, with sufficient cross-protection ($\varepsilon_{12} = \varepsilon_{21} = 0.7$ in Figure 2), and a 351 352 reasonably fast vaccine roll-out (100 days), it is best to target the more prevalent strain. 353 However, the initial advantage gained by being more prevalent dissipates rapidly as the 354 transmission rate of the second viral variant increases. Thus, when the second variant spreads 355 50% faster than the first, vaccination against the second strain is marginally better (see also Figure 1) and when the second variant spreads twice as fast as the first, vaccinating against the 356 357 faster spreading second strain dramatically reduces total deaths, as well as peak infection rates. 358 For most of the range in Figure 2, the mixed vaccination strategy is intermediate to either 359 single vaccination strategy in terms of total deaths and peak infections. However, while the difference between the mixed strategy and vaccination against viral variant 2 is minimal at $\beta_2 =$ 360 0.3 (see also Figure 1), this difference increases rapidly for $\beta_2 > 0.3$, such that, when the second 361 viral variant spreads twice as fast as the first, $\beta_2 = 0.4$, vaccinating against the second variant 362 363 save many lives, even compared to the mixed strategy. Thus, the benefits of the mixed strategy 364 seen in Figure 1 do not necessarily hold when the second viral variant is significantly more 365 transmissible. Notably, the benefit of developing vaccines against the faster spreading virus

366 emerge despite the relatively high cross-protection levels ($\varepsilon_{12} = \varepsilon_{21} = 0.7$) assumed in Figure 2 367 and despite the 100-fold greater prevalence of the first variant at the beginning of the simulation. 368 Viral times to extinction are largely independent of the transmission rate of the second 369 variant when the vaccine is targeted against this variant. This makes sense. When vaccination is 370 against the second viral variant, the final stages of the outbreak are largely determined by spread 371 of the first viral variant, meaning that the final stages of the outbreak are largely independent of 372 the properties of the second viral strain. When the vaccine in use is against the first viral variant, 373 however, the time to viral extinction is unimodal. This can be understood as follows: when the 374 second viral variant spreads slowly, it can be rapidly brought under control by cross-protection 375 from infection/vaccination against the first variant. However, rapid control through vaccination 376 is less likely when the second variant spreads more rapidly. In this case, the second variant has greater potential to infect a larger fraction of the population before cross-protection, combined 377 378 with natural immunity, finally bring the second variant under control. For faster and faster spread 379 of the second variant, however, natural immunity occurs earlier and earlier, leading to a decrease 380 in viral time to extinction.

381

382 Vaccine Roll-out

Figure 3 shows the total number of deaths (A), peak infections (B) and time to virus extinction (C) as a function of the number of people vaccinated for the virus each day. For all of the simulations in Figure 3, I assume a population size of 500,000 individuals, thus it would take 100 days to vaccinate the entire population at a rate of 5000 people/day, and 50 days to vaccinate the entire population at a rate of 10000 people/day. As expected, total deaths and peak infection rates decrease sharply with increased rate of vaccination roll-out for all vaccination strategies.




Fig. 3 (A) Total number of deaths, (B) peak infections and (C) time to virus extinction as a function of vaccine roll-out rate, $\omega_1 + \omega_2$, assuming a vaccination strategy targeting viral variant 1 (blue, slower spreading), a vaccination strategy targeting viral variant 2 (red, faster spreading) and a mixed strategy with 50% of the population receiving the vaccine against viral variant 1 and the other 50% receiving the vaccine against viral variant 2. All parameters and initial conditions except overall vaccination rate ($\omega_1 + \omega_2$) are as defined in Table 1. Results shown are median values over 30 trials.

397

398 However, over the range from 1000-5000 people/day (i.e., 500-100 days to vaccinate the population), the decrease in deaths and peak infections as a function of vaccine rollout rate is 399 400 greatest for vaccination against viral variant 2, intermediate for the mixed vaccination strategy 401 and slowest for vaccination against viral variant 1. Thus, not surprisingly, slower vaccine roll-402 outs tend to favor vaccination strategies targeting the faster spreading viral variant. This is 403 because slower vaccine roll-outs leave added time for the faster spreading variant to take over, 404 even from a significant early deficit. When the vaccine roll-out is rapid (less than two months), 405 however, all three strategies perform well. In fact, the mixed strategy outperforms both single


vaccination strategies in terms of total deaths, and outperforms vaccination against variant 2 in
terms of peak infections when the entire population can be vaccinated within 100 days. Further,
when full vaccination can be completed within ~60 days (2 months), vaccination against the first
viral variant actually leads to the lowest peak infection rates, though it still gives higher total
deaths than the mixed vaccination strategy.

411 For both vaccination against the fast-spreading virus and the mixed vaccination strategy, 412 time to viral extinction decreases with increasing vaccine roll-out rates, commensurate with the 413 expectation that faster vaccination of the population leads to faster suppression of the virus. 414 Vaccination against the first viral variant, by contrast, leads to a peak in viral extinction times as 415 a function of vaccine roll-out rate. Again, this is a result of the trade-off between rapid 416 development of herd immunity at low roll-out rates, rapid development of vaccine-induced 417 immunity at fast roll-out rates, and a peak in the middle, where vaccination slows viral spread 418 down, but does not immediately suppress it.

419

420 Initial Infection Rates

Figure 4 shows the total number of deaths (A), peak infections (B) and time to virus extinction (C) as a function of the number of people initially infected with viral variant 2. For these simulations, I keep the total number of initial infections constant, thus when there are more individuals infected with viral variant 2, there are fewer infected with viral variant 1. In order to span a wide range of variant 1: variant 2 infection ratios while maintaining at least 5 individuals infected with variant 2 (below 5 individuals, there is a sizeable likelihood of stochastic extinction of the second variant), I assume a much higher baseline infection rate in Figure 4 as compared to



430 Fig. 4 (A) Total number of deaths, (B) peak infections and (C) time to virus extinction as a 431 function of the initial number of people in the population infected with viral variant 2, $\rho_2 \sum_{i,i,k} N$, and assuming a vaccination strategy targeting viral variant 1 (blue, slower spreading), 432 a vaccination strategy targeting viral variant 2 (red, faster spreading) and a mixed strategy with 433 50% of the population receiving the vaccine against viral variant 1 and the other 50% receiving 434 the vaccine against viral variant 2. All parameters and initial conditions except initial fractions of 435 infected individuals are as shown in Table 1. For initial fractions of infected individuals, I 436 assume a constant total fraction, such that $(\rho_1 + \rho_2) \sum_{i,j,k} N = 5005$. Notice that this is a 10-437 fold higher initial infection rate than what is used in Figures 1-3. Results shown are median 438 439 values over 30 trials.

440


Figures 1-3. Specifically, in Figure 4, I assume that 1% of individuals are COVID-19 positive at the outset of the simulation, as compared to the 0.1% infection rate that I use in Figures 1-3. Despite the much higher prevalence of viral variant 1 in Figure 4, vaccinating against this variant is still generally less effective at preventing deaths. At best, vaccinating against the slow spreading viral variant 1 performs about as well as vaccinating against the fast spreading viral variant 2, and even this requires that the initial number of variant 2 infections be very low (\leq 5 total variant 2 infections and a 1000:1 ratio of variant 1 to variant 2 infections in a population of

448 500,000). More commonly, however, vaccinating against the slow spreading variant 1 leads to 449 many more deaths than vaccinating against the fast spreading variant 2. While vaccinating 450 against the slow-spreading strain is a poor strategy, the mixed vaccination strategy actually 451 outperforms both single variant strategies over a wide range of infection ratios. Indeed, up to a 452 variant 1:variant 2 infection ratio of approximately 200, the mixed strategy prevents the most 453 deaths. Interestingly, although poor in terms of preventing deaths, vaccination against variant 1 454 can actually lower peak infection rates (but see Figures 1-3), suggesting that it is not necessarily 455 a poor strategy along all public health dimensions. Initial infection ratios do not have strong 456 impacts on time to virus extinction for any of the vaccine strategies considered.

457

458 Existing Natural Immunity

459 Because COVID-19 has been spreading in most locations since February-March 2020, many 460 people have acquired natural immunity, and this could potentially alter the benefits of the 461 different vaccination strategies. I explore this effect in Figure 5. In Figures 5A,B, I assume that 462 all existing natural immunity is towards the first viral variant, with the second viral variant being 463 a very recent introduction. As expected, increasing overall rates of immunity to viral variant 1 at 464 the start of the simulation decreases both total deaths and peak infection rates. Because, however, 465 the rate of decrease is similar across all vaccination strategies, the overall level of natural 466 immunity to the first viral variant has minimal impact on the choice of vaccination strategy. In 467 Figures 5C,D, I consider a scenario where 10% of the population has natural immunity, but for 468 some fraction of individuals this immunity is targeted against viral variant 1, and for others it is 469 targeted against viral variant 2. Unlike changes in the overall levels of immunity, changes in the



470

Fig. 4 (A,C) Total number of deaths and (B,D) peak infections as a function of (A,B) the initial
fraction of the population with natural immunity to viral variant 1 and assuming no immunity to
viral variant 2 or (C,D) and the fraction of naturally immune individuals protected against viral
variant 2, assuming an overall level of natural immunity of 10%. All parameters and initial
conditions except initial fractions of naturally immune individuals are as shown in Table 1.
Results shown are median values over 30 trials.

- 477 478
- 479 relative fraction of the population that is protected against each viral variant does impact
- 480 performance of the different vaccinations strategies differently. In particular, when more of the
- 481 population is already immune to viral variant 1, it accentuates the benefit of vaccinating against
- 482 viral variant 2 and vice versa. This is because, when $\sim 10\%$ of the population has natural
- 483 immunity to viral variant 1(2), vaccinating against this variant means that ~10% of vaccines are
- 484 'wasted'. With decreasing levels of natural immunity against viral variant 1(2), however, the

485 number of wasted variant 1(2) vaccines decreases. Interestingly, despite the loss of 'wasted' 486 vaccines, vaccinating against the faster spreading second variant is still the better option for 487 preventing deaths, and remains comparable for lowering peak infection rates even when all 488 existing natural immunity is targeted against this strain. This shows how viral transmissibility 489 swamps most other considerations when determining the optimal vaccine target. Notably, 490 however, for all scenarios shown in Figure 5, vaccination against the second variant and the 491 mixed vaccination strategy are comparable, suggesting that a mixed strategy can perform as well 492 or almost as well as specifically targeting the fast-spreading strain (but see Figure 2).

493

494 **Discussion**

495 In this paper, I use a stochastic simulation to examine how the choice of vaccine target 496 impacts outcomes of an outbreak of COVID-19 consisting of two different viral variants and for 497 which vaccine cross-protection is incomplete (though not necessarily zero). Although inspired by 498 the recent emergence of the B.1.1.7 COVID-19 strain in the United Kingdom, predictions from 499 this model are not restricted to any particular viral variant. Rather, model predictions hold for 500 any virus strain that emerges and that exhibits a higher R_0 than the dominant circulating strain – a 501 typical trajectory for virus evolution. Indeed, as I write this paper, it is becoming clear that a 502 second more transmissible COVID-19 strain has emerged in South Africa²³. Like the UK B.1.1.7 503 strain, the South African variant has the N501Y mutation, although it is otherwise quite different. 504 As with increased transmission, viral variants that 'escape' current antibody responses are 505 also anticipated as a common trajectory of viral evolution. Although many scientists are hopeful 506 that existing vaccines will provide strong cross-protection against the B.1.1.7 viral variant from 507 Southern England, the South African variant appears to have even more mutations in the spike

protein. This reduces the likelihood that current vaccines will be able to neutralize it²⁴. And even if current vaccines are largely effective against both the South England and South African viral variants, as more and more of the global population becomes immune to current circulating COVID-19 strains – either through natural infection or via vaccination – the selective pressures favoring escape mutants will increase. Thus, it is almost inevitable that fast-spreading variants that are not well-covered by existing vaccines will emerge during the course of vaccine roll-out across the globe.

515 One benefit of the technologies being used to develop COVID-19 vaccines and, in 516 particular, of the mRNA vaccine approach, is the ease with which different viral variants can be 517 exchanged during vaccine development and production. However, because mRNA vaccine 518 technologies are relatively new, and have not been systematically tested in human populations 519 prior to the COVID-19 pandemic, it is not clear whether *multiple* different viral targets can be 520 included simultaneously (i.e., multivalent vaccines). Consequently, I sought to address the 521 question of which viral variant to target in the event that a vaccine can only be produced against 522 a single variant (monovalent) but there are multiple variants circulating.

523 Very broadly, my analysis suggests that it is almost always better to develop vaccines 524 that target the faster spreading viral variant. This is true even when the slower spreading variant 525 is 100- to 1000-fold more prevalent at the onset of the vaccination period and even when cross-526 protection is relatively high. This outcome is a direct result of the nature of exponential growth. 527 In particular, exponential growth rapidly accentuates even slight differences in populations with 528 different exponential growth rates (or different R_0 values, in the case of diseases). As a 529 consequence, over a matter of days to months, any initial advantage of the more prevalent but 530 slower spreading viral variant is rapidly swamped by the diverging trajectories of the viral

531 growth curves. Surprisingly, while targeting the slow spreading variant is rarely beneficial, a 532 mixed strategy, where 50% of the population receives a vaccine against one strain, and 50% 533 receives a vaccine against the other strain, can perform relatively well, at least when the 534 differences in viral transmission rates are not extreme (e.g. the second viral variant is $\leq 50\%$ more 535 transmissible than the first). That said, for more extreme differences in transmission rates, the 536 mixed strategy rapidly loses traction, and vaccination against the fast-spreading viral variant can 537 save numerous lives, as well as lower peak infection rates, even relative to the mixed strategy. 538 While most realistic scenarios that I consider suggest that it is best to develop vaccines 539 against the faster-spreading viral variant, this is not universally true. Factors that promote the 540 viability of vaccination against the slow-spreading variant include smaller differences in growth 541 rates between the two viral strains (see Figure 2), as well as faster vaccine roll-outs that leave 542 less time for the fast-spreading virus to overcome its initial lower prevalence (see Figure 3). In 543 addition, vaccination against the slow spreading viral variant is better when a larger relative 544 fraction of the population is already immune to the fast spreading viral variant, when a larger 545 relative fraction of the population is infected with the slow spreading viral variant, and when 546 cross-protection is more complete. Thus, it is not inconceivable that there would be locations 547 where vaccination against the slow spreading strain is preferable. Depending on how many 548 people in Southern England have already been infected with B.1.1.7, for example, it may be 549 more prudent to vaccinate against the original strain. Nevertheless, this appears to be the 550 exception, rather than the rule. More generally, it seems that, for a largely susceptible population, 551 and given current low rates of vaccine disbursement and delivery around the globe, it would be 552 prudent if at least some vaccine companies switched their current formulations to target the

newly emerged, highly transmissible COVID-19 variants that have been discovered in Englandand South Africa.

555 Although I designed my model to capture a range of important effects that could impact 556 the benefits of different vaccination strategies, my model does make a number of simplifying 557 assumptions. First, and foremost, I do not consider the two-dose vaccination schedule that is 558 currently in use for both the Pfizer-BioNTech vaccine and the Moderna vaccine. Rather, my 559 model ignores priming and assumes that a single vaccine dose results in a person acquiring full 560 immunity. This simplifying assumption is most appropriate if the first dose of vaccine either 561 does not provide much immunity, or else provides nearly complete protection. Predictions will 562 be less accurate, however, if the first dose provides partial immunity that is then increased by the 563 second dose. Another simplifying assumption of my model is that the population is well-mixed 564 and without any structure like age-classes or differences in behavior (e.g., ability to 565 telecommute, willingness to wear masks) that might lead to differential interactions among 566 groups or else different exposure rates or susceptibilities to exposures. As well, I do not consider 567 an exposed class or waning immunity. Likewise, I do not consider differences in infectious 568 period or disease outcomes that may be garnered by immunity, either to the infecting strain or to 569 the off-target strain. In reality, though, it is likely that vaccination would, at the very least, lower 570 death rates of an infection, even if it does not fully protect against infection itself. Another 571 assumption that I make is that, other than transmission rates, both viral variants are largely 572 identical. That is, they induce similar death rates, have similar recovery rates, and illicit similar 573 degrees of cross-protection. Finally, I assume a closed population, with no new individuals or 574 infections introduced. Many of these complexities could be added to my model, though most 575 would require additional parameters which are currently unknown. Nevertheless, as more

information becomes available about newly emerging strains, their relative transmissibilities and
the degree of cross-protection, including additional model details and complexities will become
more feasible.

579 Overall, my model suggests that, except in very rare instances, monovalent COVID-19 580 vaccines should target the fastest-spreading strain of the virus, regardless of how prevalent that 581 strain is at the outset of the vaccination period, and regardless of the degree of cross-protection 582 offered by either vaccines or natural immunity. For scenarios where targeting the slower-583 spreading strain is equivalent or even marginally better than targeting the faster-spreading strain, 584 total deaths and peak infection rates tend to be low for all vaccination strategies. However, for 585 scenarios where targeting the faster-spreading strain is best, differences in total deaths and peak 586 infections can be substantial. Thus, even from a precautionary principle, the safest bet is to target 587 the variant with the higher transmission rate. The mixed strategy – vaccinating half of the 588 population against each viral variant – performs nearly as well as vaccinating against the fast 589 spreading virus over a surprisingly large range of viral transmission rates. However, when the 590 fast spreading virus is significantly more transmissible than the original strain, even the mixed 591 strategy can result in a sizeable number of additional deaths as compared to vaccination solely 592 against the fast spreading strain. Thus, for example, for the low estimate that the B.1.1.7 strain is 593 50% more transmissible than its predecessor, the mixed vaccination strategy is nearly as good as 594 vaccination against B.1.1.7 alone. However, for the high estimate that the B.1.1.7 strain is 70% 595 more transmissible, the mixed strategy dramatically underperforms, leading to nearly 70% more deaths as compared to a strategy where all vaccine efforts are focused on the B.1.1.7 strain. 596 597 New strains of COVID-19 will continue to emerge that are more transmissible than the

598 current variants, and that escape or partially escape from the current vaccines. Although we

599	cannot prevent this fro	m happening,	we can make decisions about	t vaccination strategies that
-----	-------------------------	--------------	-----------------------------	-------------------------------

- 600 minimize the negative health outcomes of such events. Naturally, the best long-term solution will
- be to develop multivalent mRNA vaccines that simultaneously protect against all dominant
- 602 COVID-19 viral variants in circulation. Until that is possible, however, my study provides 'rule-
- 603 of-thumb' guidance for public health officials and vaccine companies alike. Specifically, my
- study suggests that, in most cases, targeting vaccines against the fastest spreading viral variant
- 605 will at worst perform equally well as other strategies and, at best, save many lives.
- 606

607 **References**

- Cucinotta, D. & Vanelli, M. WHO declares COVID-19 a pandemic. *Acta Bio Medica: Atenei Parmensis* 91, 157 (2020).
- Le, T. T., Andreadakis, Z., Kumar, A., Roman, R. G., Tollefsen, S., Saville, M. &
 Mayhew, S. The COVID-19 vaccine development landscape. *Nat Rev Drug Discov* 19, 305-306 (2020).
- 613 3 Oliver, S. E., Gargano, J. W., Marin, M., Wallace, M., Curran, K. G., Chamberland, M.,
 614 McClung, N., Campos-Outcalt, D., Morgan, R. L. & Mbaeyi, S. The Advisory
 615 Committee on Immunization Practices' Interim Recommendation for Use of Pfizer616 BioNTech COVID-19 Vaccine—United States, December 2020. *Morbidity and Mortality*
- 617 Weekly Report **69**, 1922 (2020).
- 618 4 Oliver, S. E. The Advisory Committee on Immunization Practices' Interim
 619 Recommendation for Use of Moderna COVID-19 Vaccine—United States, December
 620 2020. MMWR. Morbidity and Mortality Weekly Report 69 (2020).
- 621 5 Akpan, N. Why a coronavirus vaccine could take way longer than a year. *National Geographic* (2020).
- 6236Mahase, E. Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk624and elderly people shows. BMJ: British Medical Journal (Online) 371 (2020).
- 625 7 Mahase, E. BMJ 2020;371:m4826.
- 8 Schlake, T., Thess, A., Fotin-Mleczek, M. & Kallen, K.-J. Developing mRNA-vaccine
 technologies. *RNA biology* 9, 1319-1330 (2012).
- Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R.
 N., McCullough, M. P., Chappell, J. D., Denison, M. R. & Stevens, L. J. An mRNA
 vaccine against SARS-CoV-2—preliminary report. *New England Journal of Medicine*(2020).
- Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines—a new era in vaccinology. *Nature reviews Drug discovery* 17, 261 (2018).
- Tang, J. W., Tambyah, P. A. & Hui, D. S. Emergence of a new SARS-CoV-2 variant in
 the UK. *Journal of Infection* (2020).

636	12	Kupferschmidt, K. (American Association for the Advancement of Science, 2021).
637	13	Santos, J. C. & Passos, G. A. The high infectivity of SARS-CoV-2 B. 1.1. 7 is associated
638		with increased interaction force between Spike-ACE2 caused by the viral N501Y
639		mutation.
640	14	Jackson, C. B., Zhang, L., Farzan, M. & Choe, H. Functional importance of the D614G
641		mutation in the SARS-CoV-2 spike protein. Biochemical and Biophysical Research
642		Communications (2020).
643	15	Wise, J. (British Medical Journal Publishing Group, 2020).
644	16	Mahase, E. (British Medical Journal Publishing Group, 2020).
645	17	Sano, K., Ainai, A., Suzuki, T. & Hasegawa, H. The road to a more effective influenza
646		vaccine: Up to date studies and future prospects. Vaccine 35, 5388-5395 (2017).
647	18	Vidor, E. The nature and consequences of intra-and inter-vaccine interference. Journal of
648		<i>comparative pathology</i> 137 , S62-S66 (2007).
649	19	Gillespie, D. T. Exact stochastic simulation of coupled chemical reactions. The journal of
650		physical chemistry 81, 2340-2361 (1977).
651	20	Provention, C. C. f. D. C. a. Duration of Isolation and Precautions for Adults with
652		COVID-19, < <u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html</u> >
653		(2020).
654	21	Brazeau, N., Verity, R., Jenks, S., Fu, H., Whittaker, C., Winskill, P., Dorigatti, I.,
655		Walker, P., Riley, S. & Schnekenberg, R. P. Report 34: COVID-19 infection fatality
656		ratio: estimates from seroprevalence. (2020).
657	22	Liu, Y., Gayle, A. A., Wilder-Smith, A. & Rocklöv, J. The reproductive number of
658		COVID-19 is higher compared to SARS coronavirus. Journal of travel medicine (2020).
659	23	Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J.,
660		Doolabh, D., Pillay, S., San, E. J. & Msomi, N. Emergence and rapid spread of a new
661		severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with
662		multiple spike mutations in South Africa. medRxiv (2020).
663	24	Staff, R. UK Scientists worried vaccines may not work on S. African coronavirus variant,
664		<https: article="" td="" uk-health-coronavirus-britain-south-afri="" uk-scientists-<="" www.reuters.com=""></https:>
665		worried-vaccines-may-not-work-on-safrican-coronavirus-variant-itv-idUSKBN2990T2>
666		(2021).
667		